A breakthrough in diabetes and kidney care! The FDA has approved Semaglutide (Ozempic) to help reduce the risk of worsening kidney disease, kidney failure, and cardiovascular-related deaths in adults with type 2 diabetes and chronic kidney disease (CKD). This makes Ozempic the first and only GLP-1 receptor agonist approved for this indication.
Why This Approval Matters
✔ CKD affects 37 million adults in the U.S., with diabetes being the leading cause.
✔ 40% of people with type 2 diabetes also have CKD, increasing their risk of kidney failure and cardiovascular disease.
✔ Semaglutide offers a new treatment option to slow kidney disease progression and reduce major health risks.
Clinical Evidence: The FLOW Study
The approval is based on the FLOW phase 3b trial, which studied 3,533 adults with type 2 diabetes and CKD:
- 24% lower risk of kidney disease worsening, kidney failure, and cardiovascular death.
- 4.9% absolute risk reduction over 3 years, demonstrating significant benefits over standard treatment.
- The trial was stopped early due to strong evidence of effectiveness.
What is Ozempic?
Ozempic (semaglutide) is an injectable GLP-1 receptor agonist used for:
✔ Improving blood sugar control in type 2 diabetes.
✔ Lowering the risk of heart attack, stroke, or cardiovascular death in diabetes patients with heart disease.
✔ Now approved to slow kidney disease progression in type 2 diabetes with CKD.
Doctors and healthcare providers should consider Ozempic (Semaglutide) as a treatment option for diabetes patients with CKD.
🔹 Educate patients about kidney risks and early intervention.
🔹 Monitor kidney function regularly in diabetic patients.
🔹 Stay updated on new diabetes and CKD treatment guidelines.
This approval marks a major advancement in protecting kidney health and saving lives. Let’s work together for better patient outcomes!
To register for our next masterclass please click here https://linktr.ee/docpreneur